65,437 trials
Colorectal Cancer
Primary: Disease-free Survival — 73.4; 76.3 percentage of participants — p=0.12
Diabetes
Primary: Change in HBA1c From Baseline — 1.42; 1.34 %mmHg/dL
Respiratory Distress Syndrome, Newborn
Primary: Mortality — 5; 3; 5 Participants
Von Willebrand Disease
Primary: Ratio of Annualized Bleeding Rate (ABR) for Spontaneous Bleeding Episodes (BEs) (On-study ABR / Historical ABR) Assessed by Investigator During Prophylactic Treatment…
Dietary Habits
Primary: Percentage of Participants Who Purchase at Least 1 Sugar-sweetened Beverage for Their Child — 45; 28 percentage of participants — p=<0.01
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Postherpetic Neuralgia
Primary: Mean Pain Score on Daily Pain Rating Scale (DPRS) — 4.32; 4.22; 5.57 units on a scale — p=0.3910
Influenza · Respiratory Viral Infection
Primary: Initiate Antiviral Therapy Within 48 Hours of Symptom Onset — 8 Participants
Chalazion
Primary: The Proportions of Participants Who Experienced Complete Response of the Study Chalazion by Day 15 ± 1 — 28; 32 Participants — p=0.579
Osteochondritis Dissecans
Primary: Greater Cartilage Healing Measured by Glycosaminoglycan Content on dGEMRIC MRI
Colorectal Carcinoma
Primary: Change in Screening Metrics — 42; 8; 37; 13 Participants
Sepsis
Primary: Number of Participants With Clinical Response — 178; 169 Participants — p=0.156
Candidemia
Primary: Treatment Success at End of Study Treatment (EOST) as Determined by the Data Review Committee (DRC) — 16 Participants
Epilepsy
Primary: Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) — 84; 14; 10; 1 Participants
Breast Cancer
Primary: Percentage of Participants With Adverse Events of Primary Interest (AEPIs) — 23.1; 51.4 Percentage of Participants